CD47

CD47

a transmembrane protein without tissue specificity that is involved in membrane cation flux.
Mentioned in ?
References in periodicals archive ?
CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52u CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279
The part of the SIRP-alpha protein that floats into the synapse "gap" latches on to a receptor on the other side, called a CD47 receptor.
TTI-621 is designed to augment the immune system's ability to destroy cancer stem cells by targeting the protein CD47.
Examples of the latter include high expression of CD47 in tumor cells being associated with decreased phagocytosis by macrophages, and the expression of CD200 in tumors resulting in impaired tumor-specific effector T-cell responses.
But first, free-floating thrombospondin has to bind to CD47 on the blood cell surface.
For pig passage benchmarking, there is CDI's CD47 time based system.
Inhibrx's first immuno-oncology therapeutic is a highly differentiated antibody targeting CD47.
A protein called CD47 tells the body not to "eat" the cancer, but the antibody developed by Dr Weissman blocks CD47 and frees up immune cells called macrophages - which can then engulf the deadly cells.
Eight of these 12 highly associated SNPs were within or proximate to known genes {ADDS [adducin 3 (gamma)1, CD47 (CD47 molecule), RPS6KA2 (ribosomal protein S6 kinase, 90kDa, polypeptide 2), KLF6 (Kruppel-like factor 6), PARK2 [parkinson protein 2, E3 ubiquitin protein ligase (parkin)), MSRA (methionine sulfoxide reductase A), NRSNI (neurensin 1), and NRXNI (neurexin 1)} that likely interact through three networks (Figure 1) predicted by multiple binary protein--protein interactions as statistically associated in the curated published literature (Brennan a al.
The lead compound SIRPaFc is a fusion protein that binds to CD47 and prevents cancer cells from delivering a "do not eat" signal; in other words allowing the "destruction" of cancer cells.
But that inhibitory effect required the presence of and interaction with CD47, another cell surface protein, indicating that additional steps in the pathway remain to be identified.
a privately-held biopharmaceutical company developing proprietary and innovative biologic therapies, today provided an update on its lead cancer program - a SIRPaFc fusion protein targeting the CD47 pathway.